1. ALLA AKTIER
  2. NYHETER
  3. BICO

BICO

Nyheter BICO Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to the presentation of BICO’s Interim report Q3 2025

BICO’s Interim report Q3 2025 will be published on Tuesday November 4, 2025, at 07:00am CET. Following the release of the report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CET on the same day, with President & CEO Maria Forss and CFO Jacob Thordenberg presenting the Interim report.

Information about the presentation and webcast
The presentation will be available on BICO’s website from 09:00am CET.
https://bico.com/investors/

If you wish to participate via webcast, please use the link below: https://bico.events.inderes.com/q3-report-2025

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference. 
https://conference.financialhearings.com/teleconference/?id=5006911

For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on October 21, 2025 at 7am CEST.

About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 10,900 publications. Operating through two business areas – Lab Automation and Life Science Solutions – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
Invitation to the presentation of BICO’s Interim report Q3 2025

Datum 2025-10-21, kl 07:00
Källa MFN
Bifogade filer
Invitation to the presentation of BICO’s Interim report Q3 2025